Hwatsing Technology: A Real CMP Champion, Priced as if the Platform Story Is Already Won

Company history and financial vertical review

Hwatsing’s history has three clear stages. The first stage was technology transfer and product validation. The company was set up in April 2013, with Tsinghua-linked and Tianjin-backed shareholders signing the founding agreement in March 2013 and state-backed Tianjin capital formally participating on 2013-04-10. The purpose was direct: industrialize CMP technology. The prospectus says Tsinghua and the Tianjin government agreed to cooperate so that Tsinghua’s CMP-related technology could be commercialized. It was a mission-built commercialization vehicle for one process bottleneck, not a generic semiconductor start-up that emerged from an incubator.

The second stage was scale-up into domestic fabs. The company says its CMP equipment entered volume-production stage in 2018. The prospectus shows just how quickly the early ramp changed the financial shape of the business: revenue went from CNY 35.66 million in 2018 to CNY 210.93 million in 2019 and CNY 385.89 million in 2020. The same document shows why cash flow looked messy in the early years. CMP systems demanded heavy working-capital funding before customers reached the payment milestones tied to delivery or acceptance, and the company was still spending heavily on R&D. Operating cash flow was negative in 2018 and 2019 before turning positive in 2020, a normal pattern for a tool vendor crossing from R&D to customer fabs but not for a distributor or software story.

The third stage began with the STAR listing and is still running now: platform expansion around a proven CMP base. The IPO listed the company on 2022-06-08 at CNY 136.66. The original capital-markets pitch was clean and narrow: China’s domestic 12-inch CMP supplier coming to public market in a segment where Applied Materials and Ebara still dominated. The company’s own IPO risk section said those two foreign incumbents together held more than 90% of global CMP equipment share, and Hwatsing’s mainland CMP share had climbed from about 1.05% in 2018 to 6.12% in 2019 and 12.64% in 2020. The point of the IPO story was import substitution in a hard process step, not breadth.

What changed after listing was less the CMP thesis than management’s ambition around it. The 2025 annual report now describes a company offering CMP, thinning, ion implantation, dicing, edge polishing, wet tools, wafer regeneration, and critical consumables and maintenance services. The 2026 A-share fundraising plan makes the same point in capital-allocation language. The Shanghai base is meant to strengthen ion implantation, CMP and thinning production and R&D. The Kunshan project will add another 200,000 wafers a month of initial wafer-regeneration capacity. The R&D project is explicitly aimed at advanced front-end manufacturing, advanced packaging, key components and consumables.

That platform move has had two meaningful turning points, and the first was acquisition. In December 2024, Hwatsing announced that it would spend up to CNY 1.0045 billion to acquire the remaining 82% of ChipY Semiconductor Shanghai, turning an associate into a wholly owned subsidiary. The rationale in the announcement and completion notice was straightforward: accelerate layout in ion implantation equipment and deepen the “equipment + services” platform. Completion was announced on 2025-03-31. Press reports described the valuation as a very large premium to book, and another issuer’s later public filing cited a 100% valuation of CNY 1.225 billion against net assets of CNY 74.63 million, implying a premium above 1,500%. That corroborates the direction of the premium claim, but because that ratio does not come from Hwatsing’s own transaction announcement, it should be treated as secondary corroboration, not as primary deal disclosure.

The other turning point was financing and governance. In 2025, the company’s leadership changed materially: longtime chairman Lu Xinchun left, general manager Zhang Guoming left, and Wang Tongqing became chairman and general manager. At the same time, the company stepped up shareholder-return signaling. The 2025 annual report proposed a cash dividend and a 10-for-4 bonus issue, and the active buyback plan approved in late 2025 authorized CNY 50 million to CNY 100 million of repurchases for employee stock ownership plans, equity incentives, or conversion of future convertible bonds. By 2026-06-30, the company had bought back 441,120 shares for CNY 60.22 million, leaving roughly CNY 39.78 million of remaining headroom under the authorized ceiling. The purpose is balance-sheet-backed capital management around incentives and future financing flexibility, not cancellation.

One important 2026 event needs careful handling because the public record is incomplete. On 2026-06-09, company news distributed through financial media said Hwatsing had won China’s first fully automatic 510×515mm panel-level CMP production order, for the Master-P510APEX system, from an “important advanced-packaging customer,” and that the system would go into a client production line for mass-production use. That is strategically important because it extends Hwatsing’s polishing capability from wafers into panel-level advanced packaging. But the public announcement did not disclose the customer identity, order scope, order value, or the expected revenue-recognition schedule. One trade-media article later cited an amount of CNY 60.22 million, but that figure is unconfirmed in primary disclosure and is suspiciously identical to the buyback cash total disclosed elsewhere. I do not rely on that amount. The right conclusion is narrower: the order appears genuine, the strategic significance is high, and the commercial size remains unverified.

The financial record since the company became a scaled listed business holds up well, but it is not simple. The three-year revenue path is clean: CNY 2.51 billion in 2023, CNY 3.41 billion in 2024, and CNY 4.65 billion in 2025. Net profit followed, rising from CNY 723.7 million to CNY 1.023 billion and then CNY 1.084 billion. Gross margin stayed above 40%, though it drifted down in 2025 as costs rose with scale and mix. Return on equity also eased, from 17.04% in 2024 to 15.52% in 2025, because the equity base grew faster than profit. This reflects normal maturation, not margin collapse: a company scaling adjacent lines while still defending its gross-profit structure.

Cash conversion is where the vertical read becomes more nuanced. Operating cash flow was CNY 652.9 million in 2023, CNY 1.155 billion in 2024, and CNY 799.8 million in 2025. Over those three years combined, operating cash flow equaled about 0.92x net profit, acceptable but not flawless, and the 2025 cash-flow bridge shows why. Inventory absorbed CNY 729.4 million of cash and operating receivables absorbed another CNY 426.3 million, partly offset by a CNY 698.5 million increase in operating payables. In plain English, Hwatsing is still a company that often funds growth ahead of collections. That fits the physics of semiconductor tools, but it also means investors should resist treating accounting profit as pure free cash generation.

Balance-sheet quality is good enough to support expansion, but it is not an idle balance sheet. Total assets reached CNY 13.14 billion at the end of 2025, with net assets at CNY 7.46 billion. The 2026 financing document shows a 2026-03-31 current ratio of 2.13x and an asset-liability ratio of 42.98% on a consolidated basis. Fixed assets rose sharply to CNY 1.535 billion by end-2025 from CNY 965.3 million a year earlier, while construction in progress fell from CNY 372.7 million to near zero as projects came into service. Capital spending paid in cash was CNY 222.2 million in 2025, while fixed-asset depreciation plus amortization and long-term expense amortization added up to roughly CNY 157.1 million. That suggests current capex is still carrying a growth component, not merely a maintenance burden.

The capital-market history mirrors that business history. The first phase was IPO excitement around domestic substitution. The second was fundamental validation as revenue and profit compounded. The third is rerating around platform optionality. The stock touched an all-time high of CNY 356.64 on 2026-07-01 and then fell back to CNY 267.50 by 2026-07-03, but even after the pullback it remained at about 120.6x trailing earnings and around the 99th percentile of its listed-period P/E history. That is the giveaway: the market is no longer valuing Hwatsing as a proven CMP grower; it is valuing the company as a future domestic process platform whose new lines will land on schedule.

Business model, industry, and moat

Hwatsing’s business model is easiest to understand as a two-layer machine. The first layer is the sale of difficult process equipment into domestic semiconductor manufacturing and advanced-packaging lines. The second layer is the installed-base annuity that forms once those tools are running: wafer regeneration, maintenance, spare parts, consumables and service support. In 2025, that second layer was still much smaller than the first, but it was the faster-growing and higher-margin piece. That matters because equipment companies become sturdier when more of their gross profit comes after the initial tool sale. Hwatsing is not there yet, but the direction is visible.

The revenue structure confirms the transition but also the concentration. Equipment was 87.2% of 2025 revenue; services were 12.8%. Mainland China accounted for 99.1% of sales. The sales model was effectively all direct sales. Those numbers say three things at once. First, the company’s home market matters overwhelmingly more than overseas optionality. Second, the service mix is meaningful enough to talk about, but still too small to mute a genuine capex downturn at domestic fabs. Third, customer-facing capability is direct and hands-on, not channel-led. In semiconductor tools, that is usually a strength because process debugging and on-site response time matter.

The moat holds up best in four places.

The moat starts with process know-how that crossed from lab science into fab qualification. CMP is far more than another mechanical tool: it is a yield-critical planarization step where small deviations can cascade through lithography and interconnect reliability. Hwatsing’s annual report says its 12-inch CMP products now cover advanced and mature process nodes, and the company describes batch applications in advanced logic, advanced memory and advanced packaging. The installed proof matters more than the patent count. Plenty of Chinese equipment companies can show a research pipeline. Fewer can show repeated use in production fabs.

A second source is domestic customer co-development paired with local service response. The company’s disclosures repeatedly connect its competitive position to deep participation in customer production-line process development. This matters more than it sounds: in semiconductor equipment, gaining a slot on the line is half the battle, and staying there through defect-control, uptime and process-yield tuning is the rest. A domestic vendor that can iterate quickly with Chinese fabs has an advantage that import restrictions only reinforce. That advantage is not invincible, but it is durable.

A third comes from installed-base spillover into consumables and services. The 2026 placement document spells it out: CMP and thinning tools consume specialized wearing parts, and those parts need periodic replacement to maintain performance. Once that installed base gets broad enough, the company is no longer bidding only for new-capacity capex; it is also collecting recurring spend from tools already in service. That is the most convincing path to smoother earnings quality, and it is also why the service segment’s faster growth matters more than its present size.

The fourth is policy alignment, and it is a conditional moat rather than a permanent one. BIS tightened semiconductor equipment controls again in late 2024, including new controls on 24 types of semiconductor manufacturing equipment and additional Entity List actions. CSIS summarized the broader policy logic clearly: the restrictions limit China’s access to advanced Western tools and are also meant to hinder China’s own development of advanced semiconductor manufacturing equipment. For Hwatsing, that cuts both ways. In the near to medium term, tighter controls on foreign tools strengthen domestic substitution demand. Over a longer horizon, a successful Chinese equipment company could itself become a more explicit target of technology denial, component restrictions or customer-side pressure. Policy is helping the demand story now, but it is also a structural source of future risk.

Governance is better than many investors assume when they hear “state-controlled A-share semiconductor company,” but it still carries a governance discount. The 2026 financing document says Qingkong Venture directly held 28.12% of the company as of 2026-03-31 and that the actual controller is Sichuan SASAC through the controlling shareholder chain. That is more stable than a founder-dominated small cap, and the 2025 annual report shows a standard unqualified audit opinion, no special governance arrangements, and no securities-regulator penalties in the last three years. Still, the company is not controlled by dispersed market shareholders; it sits inside a state-capital structure where strategic goals and financing decisions can matter as much as pure near-term return metrics.

The industry backdrop remains supportive. The 2026 placement sponsor document cites SEMI forecasts showing global semiconductor manufacturing equipment sales rising 13.7% in 2025 to $133.0 billion, with 2026 first-quarter global equipment shipments at $36.55 billion, up 14% year on year, and it says mainland China has remained the world’s largest semiconductor-equipment market for several years. For Hwatsing, that matters more than global smartphone demand or consumer chip cycles in the abstract. The question that counts is whether Chinese fabs and packaging houses keep spending on line build-outs, process migration and localization. On that metric, the cycle still looks better than normal industrial capital goods.

Horizontal competitor analysis

Hwatsing does not sit in a crowded field of direct CMP-listed peers. The practical competitive set is mixed. Its true direct process competitor in CMP remains foreign, especially Applied Materials and Ebara. Its domestic listed peer set is instead a set of adjacent process-tool champions that investors use as valuation reference points: AMEC, ACM Research Shanghai and NAURA. The right horizontal method is to ask what each company has become, why customers choose each one, and what that says about Hwatsing’s niche, not to pretend these companies are identical.

AMEC has become China’s most internationally legible high-end process-tool company. Its strength is deep process credibility in etch, and increasingly in deposition, not breadth for its own sake. Public results for 2025 showed revenue of about CNY 12.39 billion and net profit of about CNY 2.11 billion. By early July 2026 the stock was trading around CNY 413.69 with a market cap around CNY 387.6 billion and a TTM P/E around the mid-140s. Customers choose AMEC when etch performance and advanced-node process results matter. The market gives it a premium because it sees global-grade technology with potentially larger offshore credibility than most China tool makers.

ACM Research Shanghai is a different animal. It has become a domestic player in cleaning, plating and related wet-process equipment, with a more diversified wet-tool and packaging-leaning process profile than Hwatsing’s CMP-first base. Its 2025 annual report showed revenue of CNY 6.786 billion and net profit of CNY 1.396 billion. Official SSE quote data showed the stock at CNY 370.00 on 2026-07-02, while Sina’s market page showed a market value around CNY 178.6 billion and a TTM P/E near 142x around the same period. Customers choose ACM for front-end and packaging cleaning and related wet-process applications, not for planarization leadership. The market treats it as a high-growth tool specialist rather than a pure localization substitute.

NAURA has become the broadest domestic platform in the group. Its 2025 revenue was about CNY 39.35 billion and net profit about CNY 5.52 billion. Around the research date, public quote sources showed the shares near CNY 816–841 and market value near CNY 592 billion, with TTM P/E a little above 106x. Customers choose NAURA because it can show up as a domestic “one-stop” process-equipment vendor across etch, deposition, thermal, wet and ion implantation. Its strength is breadth, scale, purchasing power and cross-sell within customer capex plans. The market values the platform itself, not NAURA winning every segment.

Against that group, Hwatsing’s niche is narrower but sharper. Customers do not choose Hwatsing because it offers the broadest line card. They choose it because in one process family that matters enormously, CMP, it has become credible enough to displace imports in domestic fabs. That is a better niche than many investors appreciate. CMP is not glamorous the way etch or deposition can be, but it is yield-critical, qualification-heavy and sticky once embedded. The reason Hwatsing deserves to be valued above many generic “国产替代” stories is that replacing a CMP incumbent inside a fab is hard. The reason it should still trade below NAURA in strategic optionality is that Hwatsing has yet to prove broad multi-process dominance across front-end tool categories.

Business shape matters more here than headline valuation. AMEC monetizes depth in a highly strategic advanced-node step. NAURA monetizes range. ACM Shanghai monetizes specialized wet-process leadership. Hwatsing monetizes mastery in planarization and is now trying to propagate that customer trust into neighboring tool categories plus recurring services. That propagation is plausible. It is not fully demonstrated. The annual report’s refusal to disclose per-product revenue inside the equipment bucket is exactly what keeps the platform thesis from being fully bankable today. If Hwatsing one day discloses that non-CMP tools and services account for a much larger share of gross profit than investors assume, the stock can defend higher multiples for longer. If not, it risks being valued like a platform while still earning like a specialist.

The peer numbers underline the issue.

The table below combines the latest public annual results with market data sourced around the research date. Dates differ slightly by source and market close, so the table is for cross-sectional comparison rather than precise trading execution.

The business reading behind the table is more important than the table. Hwatsing is smaller than every domestic comparator in revenue and market value, yet it trades at a trailing multiple higher than NAURA and not far from AMEC and ACM Shanghai. That only makes sense if the market believes Hwatsing’s future mix shift will be unusually powerful. The current price is asking investors to underwrite a transition from CMP specialist to broad platform before the segment disclosures fully show the economics of that transition. That is the core horizontal conclusion.

Current fundamentals, valuation, risks, catalysts, key data, uncertainties, and sources

The last four reported quarters show a business still growing, but with the shape of the growth changing. In 2025, revenue climbed 36.46% to CNY 4.648 billion, while net profit rose only 5.89% to CNY 1.084 billion and operating cash flow dropped 30.73% to CNY 799.8 million. The reason was not demand failure: the annual report spells out that procurement payments and payroll rose, while the cash-flow reconciliation shows large working-capital absorption from inventory and receivables. Then in 2026 Q1, revenue rose again to CNY 1.201 billion, up about 31.7% year on year, but net profit grew just 5.95% and operating cash flow was a modest CNY 7.9 million. This is the kind of quarterly pattern that can sit comfortably next to a good long-term story and still punish a richly valued stock if investors expect smoother conversion.

Earnings growth alone does not capture what the market is trading right now: a compound theme of domestic substitution, tool-platform expansion, advanced-packaging optionality and capital-markets scarcity value for high-quality A-share semiconductor equipment names. The June 2026 panel-level CMP order fed that theme. So did the active buyback. So did the April 2026 shift from an H-share plan to a domestic A-share financing plan, which signaled management’s intention to keep expanding aggressively in China rather than optimize for a second listing. The risk is that some of this is narrative velocity rather than disclosed revenue. The panel-level order, for example, may well matter strategically and still do very little for near-term reported earnings if customer acceptance or scale deployment takes time. The company has not disclosed customer name, order value, or recognition timing.

A short data snapshot helps anchor the discussion. The figures below are compiled from the annual report, the 2026 Q1 report, and the buyback progress disclosure.

The business reason behind those numbers is that Hwatsing is trying to do two expensive things simultaneously: defend a still-growing CMP franchise and fund a broader platform buildout. Investors who focus only on revenue growth will miss the working-capital drag. Investors who focus only on the cash drag will miss the fact that the company is still scaling service and adjacent tools from a sturdier base than most domestic peers had at the same stage.

Valuation is the part of the case where the evidence points one way. The market is assigning Hwatsing a multiple that assumes several more years of delivery before delivery is visible in segment detail. Around the research date, the stock traded at about 120.6x trailing earnings, while Lixinger’s history put that near the 99th percentile of the listed period, with the listed-period 80th-percentile P/E around 54x. Even if one adjusts for the STAR Market’s higher valuation regime, a multiple in this zone only works if investors believe that CMP leadership, service monetization, adjacent-tool ramp and domestic capex conditions will all stay favorable at the same time. That bundle of assumptions is too generous for a capital-intensive tool name.

Cash-flow passthrough does not rescue the valuation. Over 2023–2025, operating cash flow was about 0.92x net profit. That is not perfect, but it does not force a full switch to a harsher owner-earnings basis. Maintenance capex appears lower than total capex because fixed assets stepped up materially while construction in progress came down, indicating growth projects moving into service. Using 2025’s roughly CNY 157 million of depreciation and amortization as a maintenance proxy, owner earnings are broadly similar to reported earnings rather than dramatically smaller. So the valuation problem is not an accounting mirage: the headline earnings multiple is simply already stretched.

The scenario framework below is a research exercise, not investment advice. It uses a three-year horizon because the company is still shifting product mix and capacity footprint.

The scenario table matters less for its exact endpoint than for this: today’s price already sits above what even a generous three-year operating outcome supports. A good company can still be a poor stock if the entry price leaves no room for delays, mix disappointments or a normal valuation reset.

Margin of safety, checked separately, is absent. The current price is far above the value implied by the conservative scenario. If one cuts the base-scenario earnings assumption to 70%, the implied value falls toward the low-CNY-130s, which is roughly half the current quote. If earnings were flat for the next three years and the stock merely de-rated toward the listed-period upper historical band, investor returns would be poor even without a downturn in the business itself. This is the definition of a good-company-bad-price case. The margin-of-safety sufficiency verdict is: none.

The major permanent-capital risks are specific, not abstract. The first is adjacent-tool disappointment. The annual and financing documents clearly show management wants thinning, ion implantation, wet tools and services to deepen the platform. If those lines stay technically credible but commercially small, the market can no longer justify paying platform multiples on CMP-heavy economics. Probability medium; impact high. The observable indicator is whether future annual reports begin disclosing more meaningful non-CMP mix detail or keep hiding broad equipment economics inside one segment.

The second is cash-conversion strain. In 2025, inventory absorbed CNY 729.4 million of cash and operating receivables absorbed CNY 426.3 million. That is tolerable in a ramp, but if the same pattern persists while growth moderates, cash generation will lag profit and capital-market tolerance will shrink. Probability medium; impact high. Watch operating cash flow versus net profit and watch whether inventory growth keeps outrunning revenue growth.

The third is policy reversal of the “helpful restriction” kind. Export controls are currently tailwind and threat at the same time. They push domestic customers toward Chinese tools, but they also aim to slow China’s development of advanced semiconductor manufacturing equipment. If component access tightens on Chinese tool makers themselves, or if restrictions expand from foreign suppliers to Chinese equipment ecosystems, Hwatsing’s cost, development pace and customer deployment could all be hit. Probability medium; impact high. The observable indicators are BIS rule changes, entity-list additions, and changes in customer qualification cycles.

The fourth is financing execution risk. The April 2026 private-placement plan is ambitious, but the June 2026 sponsor document says the Shanghai project land-use right had not yet been obtained and related land, filing and environmental procedures were still in process. Probability medium; impact medium. Delayed land or delayed capital raising would not break the company, but it could delay the capacity and R&D roadmap the stock is already pricing.

The positive catalysts are obvious. Clear evidence that service revenue has become a larger share of gross profit would help. A verified commercial ramp in panel-level CMP would do more for the stock than a headline order. Faster-than-expected ion implantation progress from the ChipY acquisition points the same direction. A deeper buyback, or a more shareholder-friendly use of the remaining authorization, would help sentiment at the margin. Most important would be a clean 2026–2027 cash-conversion recovery, because it would answer the sharpest bear complaint directly.

The negative catalysts are just as clear. A quarter where revenue still grows but cash flow and margin deteriorate again would be dangerous in a 100x-plus earnings stock. Any indication that the panel-level CMP order is still only engineering validation dressed up as mass-production use would matter, and so would a softening in Chinese semiconductor equipment demand. A more aggressive export-control round that touches Chinese tool makers more directly would matter too, as would a weak outcome on the planned private placement.

A tracking dashboard is more useful than another paragraph of opinion.

The dashboard below uses current company disclosures and market data. The next scheduled earnings date comes from public market-calendar sources around the research date.

Why these matter is straightforward. Revenue and profit growth tell you whether customer demand still runs hot. Cash conversion is the read on whether that growth is healthy. Service mix shows whether the installed-base annuity is becoming tangible. Buyback and financing execution show how management is balancing expansion with shareholder claims. The panel-level CMP item is the cleanest “second growth curve” signal in the entire current narrative, and valuation matters because for a stock already trading at the edge of its own historical range, even good results can disappoint if they are merely good.

Research uncertainties deserve plain language. The first blind spot is product mix. Primary filings no longer disclose CMP versus thinning versus ion implantation versus wet-tool revenue separately. The second is current CMP market share. The latest primary numeric mainland share I found was 12.64% for 2020; recent reports only say the share kept rising. The third is the June 2026 panel-level CMP order value and customer identity, neither of which are disclosed in primary sources. The fourth is precise sell-side estimate revision data after the latest quarter; public primary materials do not provide a clean consensus-revision series. The fifth is acquisition economics for ChipY beyond the announced maximum consideration and completion; the exact realized consideration path is not fully transparent in primary disclosure.

Primary sources for this report were the company’s 2025 annual report, the 2026 first-quarter report, the July 2026 buyback progress announcement, the 2026 A-share financing documents, the 2021 IPO prospectus and listing materials, the December 2024 and March 2025 ChipY acquisition disclosures, official or near-official market quote pages for current prices, and official BIS material on export controls, supplemented by reputable financial media where primary disclosure was incomplete.

Cross-synthesis summary

Looking back across its history so far, the capability Hwatsing has genuinely proven is narrower than the market’s dream, but stronger than the skeptics’ caricature. It has proven that it can take a Chinese-developed CMP technology stack, qualify it into important domestic semiconductor lines, scale revenue into the multi-billion-renminbi range, remain profitable while holding R&D around 12% of sales, and start building a service layer around its installed base. None of this is luck, and it is not purely policy either: it is a genuine operating achievement in one of the hardest corners of semiconductor equipment. Credibility came from fabs accepting its tools, not from the market wanting a domestic story.

Its past success came from a combination of technology transfer that was unusually focused, favorable domestic policy, rising Chinese fab capex, and management’s willingness to reinvest rather than milk a niche. Those success factors are still present, but they no longer point in exactly the same direction. Policy is still useful, but also riskier because successful Chinese equipment firms are now more visible in the geopolitics of technology denial. Chinese fab spending has not let up, but at a stock level the easy rerating from “domestic substitute” to “real company” has already happened. What matters now is a harder question: can Hwatsing translate CMP trust into durable earnings streams from adjacent tools and services before valuation patience runs out.

Horizontally, Hwatsing’s true advantage over domestic peers is specialization in a process step that is both hard and sticky. That is not the same as being the most important domestic equipment company overall. NAURA is broader. AMEC is deeper at the global frontier in its core process domain. ACM Shanghai is more identified with wet-process leadership. Hwatsing’s edge is that CMP replacement is technically painful, customer-specific and not easily commoditized once embedded. Its weakness is that the market is already granting it platform credit that still exceeds the evidence in its segment disclosure. That weakness is temporary if non-CMP tools and services become visibly larger in the P&L. It is structural if, three years from now, the business is still mainly a CMP company reported as a generic “equipment” segment.

The market is probably right that Hwatsing can keep growing; what is actually in doubt is the quality and visibility of that growth. The stock appears to be rewarding future platform scale today rather than waiting for the disclosures to show it. That is why the panel-level CMP order became such an excitable headline. Investors are looking for proof that the franchise is expanding into new process territory. The problem is that public details remain thin. If that order is the first of many, current excitement will turn out early. If it is still nearer to pilot-scale learning than many bulls assume, the stock has spent valuation credit in advance.

The critical variables differ by time horizon. Over the next year, the questions that matter are cash conversion, the cadence of adjacent-tool commercialization, and whether management can advance the private-placement plan without dilutive disappointment or project delay. Over three years, the decisive issues are service-mix expansion, ion-implantation integration after the ChipY acquisition, and whether the company becomes visibly less dependent on CMP-heavy economics. Over five years, the decisive issue is whether Hwatsing can become a domestic process-platform name with recurring revenue characteristics, rather than merely a periodically rerated specialist.

The company would become a better investment under two conditions. One is easier: a much lower price. The other is harder: better disclosure showing that service and adjacent-tool economics are genuinely scaling. A price correction without business damage would improve the setup immediately. A sustained rise in service weight, better cash conversion, and hard evidence that the panel-level CMP and ion-implantation lines are turning into recurring revenue would justify paying up more than I am willing to pay today. The original judgment should be re-examined if cash conversion recovers meaningfully, if product mix becomes more transparent and favorable, or if export-control policy begins to strike Chinese tool makers more directly than it has so far.

The core bull reasons are clear. Hwatsing has already crossed the hardest threshold for a Chinese CMP vendor: real production-line acceptance in domestic fabs. Service revenue is still small but is growing faster than equipment and carrying higher margin. Management is deploying capital toward a broader tool-and-service footprint rather than defending a shrinking niche. The Shanghai, Kunshan and R&D projects show a coherent industrial logic. And domestic semiconductor spending plus localization policy still create a better home market than most industrial-equipment companies enjoy.

The bear reasons are just as concrete. First, primary disclosures do not show the precise current revenue contribution of CMP versus the new tool lines, so the platform thesis remains partially opaque. Second, 2025 and 2026 Q1 showed weak cash conversion relative to the market’s quality expectations, with large cash absorption in inventory and receivables. Third, the stock trades near the top of its own historical valuation range, at a level that assumes clean execution across several moving parts. Fourth, geopolitical risk is central, not peripheral: the same export-control regime that helps domestic substitution also explicitly seeks to impede China’s development of advanced semiconductor manufacturing equipment. Fifth, the June 2026 panel-level CMP order is strategically important but commercially under-disclosed.

If this investment is down 50% three years from now, the far likelier culprit is an execution-and-multiple compression story, not a scandal. Script one: by 2027, CMP still grows, but ion implantation and panel-level CMP remain small, service mix stalls near the low teens, and operating cash flow stays below net profit as working capital consumes cash. The market stops paying platform multiples for specialist economics. A P/E falling from around 120x to 50x on only modestly higher EPS could more than halve the share price. Script two: another round of export controls or component restrictions slows customer qualification cycles and raises engineering costs just as domestic capex cools. Revenue growth decelerates toward the teens, gross margin slips, and the stock de-rates toward its historical upper band rather than its current momentum peak. That also gives you a 50% loss path without any fraud or bankruptcy in sight.

The final judgment is direct. Hwatsing is a real semiconductor-equipment franchise built on one of the hardest process steps in the fab, and it is doing sensible things with that franchise: broadening into adjacent tools, building service revenue, adding ion implantation through acquisition, and investing for more capacity and faster customer response. I would not dismiss the stock as hype. The company has earned its relevance.

I still would not own it at the current price. The valuation is paying in advance for a version of Hwatsing that the filings have not yet fully shown. When a company that generated CNY 1.084 billion of 2025 net profit and CNY 799.8 million of operating cash flow is valued at about CNY 132.3 billion, the burden of proof moves from management to the stock. What worries me more than operational collapse is the chance that perfectly decent execution still fails to satisfy an already extravagant price. What would change my mind is either a substantially lower entry point or a few more reporting periods that prove the transition from CMP-led grower to broader platform supplier in hard segment economics rather than narrative.

【Company-profile scores】

• Fundamental quality: high
• Growth: high
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: high
• Suitable investor type: not suitable for the general investor

【Investment rating】

• Rating: Avoid
• One-line thesis: A strong CMP franchise and credible platform ambition are already more than fully discounted in a stock trading near the extreme end of its own valuation history.
• 【Ideal Buy Price】110–125 CNY
• Basis: This range is at least a 20% discount to the conservative three-year fair-value case of about CNY 140 per share.
• Acceptable hold price: 155–205 CNY
• Clearly overvalued price: 262 CNY and above
• Current-price classification: clearly overvalued
• Whether to wait for a better price: yes; I would wait for a price below CNY 125, or for two things to happen together above that level: service/share-of-profit becoming visibly larger and cash conversion normalizing. The opportunity cost of waiting is missing a continued momentum run in A-share semicap names.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about -19%; base about -12%; optimistic about -4%
• Max-loss risk: 50% to 60%, triggered by a combination of adjacent-tool under-delivery, weak cash conversion and a normal P/E compression toward the company’s own historical upper range rather than today’s momentum valuation.
• Reassessment-trigger signals: if service revenue rises above 18% of total with gross margin still above 47%; if operating cash flow exceeds net profit over a rolling 12-month period; if non-CMP tool contribution becomes materially clearer in disclosure; if the panel-level CMP order converts into repeat disclosed orders; if export controls begin to target Chinese equipment makers more directly.

【Valuation Range】

• current: 267.50 (close as of 2026-07-03)
• bear (conservative · ideal buy zone): [110, 125]
• base (fair · acceptable hold zone): [155, 205]
• bull (optimistic · above the clearly-overvalued line): [262, 320]

Other tickers mentioned

• 688012.SHG: AMEC, used as a domestic high-end process-tool peer and valuation reference.
• 688082.SHG: ACM Research Shanghai, used as a domestic wet-process and packaging-related tool peer.
• 002371.SHE: NAURA, used as the broadest domestic semiconductor-equipment platform peer.
• AMAT.US: Applied Materials, used as the global CMP and broader process-equipment reference.
• 6361.TSE: Ebara, used as a global CMP incumbent reference from the IPO competitive-disclosure context.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.